Taurine and glutathione levels in plasma before and after ECT treatment

Psychiatry Research

Volumn 198, Issue 1, 2012, Pages 53-57

  Samuelsson, Martin ^a,b   Gerdin, George ^a,b   Öllinger, Karin ^a,b   Vrethem, Magnus ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Department of Clinical Immunology and Transfusion Medicine   (Sweden)

Author keywords

Depression; ECT; Glutathione; Taurine

Indexed keywords

GLUTATHIONE; TAURINE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; DEPRESSION; DISEASE SEVERITY; DOWN REGULATION; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSION; ELECTROCONVULSIVE THERAPY; FEMALE; GLUTATHIONE; HUMANS; MALE; MIDDLE AGED; PHLEBOTOMY; PSYCHIATRIC STATUS RATING SCALES; STATISTICS, NONPARAMETRIC; TAURINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84867143011     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.02.016     Document Type: Article

References (45)

1. Akerboom T.P., Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods in Enzymology 1981, 77:373-382.
2. Albrecht J., Wegrzynowicz M. Endogenous neuroprotectants in ammonia toxicity in the central nervous system: facts and hypotheses. Metabolic Brain Disease 2005, 20:253-263.
3. Altamura C., Maes M., Dai J., Meltzer H.Y. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. European Neuropsychopharmacology 1995, 5:71-75.
4. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington, DC. fourth edition.
5. Atmaca G. Antioxidant effects of sulfur-containing amino acids. Yonsei Medical Journal 2004, 45:776-788.
6. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Bush A.I. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biological Psychiatry 2008, 64:468-475.
7. Bettler B., Kaupmann K., Mosbacher J., Gassmann M. Molecular structure and physiological functions of GABA(B) receptors. Physiological Reviews 2004, 84:835-867.
8. Brattström L.E., Israelsson B., Jeppsson J.O., Hultberg B.L. Folic acid-an innocuous means to reduce plasma homocysteine. Scandinavian Journal of Clinical and Laboratory Investigation 1988, 48:215-221.
9. Dinan T. Inflammatory markers in depression. Current Opinion in Psychiatry 2008, 22:32-36.
10. Dringen R. Metabolism and functions of glutathione in brain. Progress in Neurobiology 2000, 62:649-671.
11. Ekberg M., Jeppsson J., Denneberg T. Penicillamine treatment of cystinuria. Acta Medica Scandinavica 1974, 195:415-419.
12. Hestad K.A., Tønseth S., Støen C.D., Ueland T., Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. The Journal of ECT 2003, 19:183-188.
13. Honegger C.G., Langemann H., Krenger W., Kempf A. Liquid chromatographic determination of common water-soluble antioxidants in biological samples. Journal of Chromatography 1989, 487:463-468.
14. Ishihara K., Sasa M. Mechanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Japanese Journal of Pharmacology 1999, 80:185-189.
15. Januel D., Poirier M.F., D'alche-Biree F., Dib M., Olié J.P. Multicenter double-blind randomized parallel-group clinical trial of efficacy of the combination clomipramine (150 mg/day) plus lithium carbonate (750 mg/day) versus clomipramine (150 mg/day) plus placebo in the treatment of unipolar major depression. Journal of Affective Disorders 2003, 76:191-200.
16. Jeppsson J.O., Karlsson I.M. Ion-exchange chromatography of physiological sulphur amino acids on a highly crosslinked resin. Journal of Chromatography 1972, 72:93-103.
17. Keller M.B. Past, Present, and Future Directions for Defining Optimal Treatment Outcome in Depression: remission and beyond. JAMA 2003, 289:3152-3160.
18. Kendell S.F., Krystal J.H., Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion on Therapeutic Targets 2005, 9:153-168.
19. Kodydková J., Vávrová L., Zeman M., Jirák R., Macášek J., Staňková B., Tvrzická E., Žák A. Antioxidative enzymes and increased oxidative stress in depressive women. Clinical Biochemestry 2009, 42:1368-1374.
20. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends in Neurosciences 2002, 25:154-159.
21. Kuloglu M., Ustundag B., Atmaca M. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochemistry and Function 2002, 20:171-175.
22. Lehtimäki K., Keränen T., Huuhka M., Palmio J., Hurme M., Leinonen E., Peltola J. Increase in plasma proinflammatory cytokines after electroconvulsive therapy in patients with depressive disorder. The Journal of ECT 2008, 24:88-91.
23. Lima L., Obregón F., Urbina M., Carreira I., Baccichet E., Peña S. Taurine concentration in human blood peripheral lymphocytes: major depression and treatment with the antidepressant mirtazapine. Advances in Experimental Medicine and Biology 2003, 526:297-304.
24. Maes M., Verkerk R., Vandoolaeghe E., Lin A., Scharpé S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatrica Scandinavica 1998, 97:302-308.
25. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Kubera M., Bob P., Lerer B., Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metabolic Brain Disease 2009, 24:27-53.
26. Miao N., Nagao K., Lynch C. Thiopental and methohexital depress Ca2+ entry into and glutamate release from cultured neurons. Anesthesiology 1998, 88:1643-1653.
27. Mills B.J., Lang C.A. Differential distribution of free and bound glutathione and cyst(e)ine in human blood. Biochemical Pharmacology 1996, 52:401-406.
28. Mitani H., Shirayama Y., Yamada T., Maeda K., Ashby C.R., Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Progress in Neuro-psychopharmacology and Biological Psychiatry 2006, 30:1155-1158.
29. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. The British Journal of Psychiatry 1979, 134:382-389.
30. Nestler E., Carlezon W. The Mesolimbic Dopamine Reward Circuit in Depression. Biological Psychiatry 2006, 59:1151-1159.
31. Palmio J., Huuhka M., Saransaari P., Oja S.S., Peltola J., Leinonen E., Suhonen J., Keränen T. Changes in plasma amino acids after electroconvulsive therapy of depressed patients. Psychiatry Research 2005, 137:183-190.
32. Pandya M., Pozuelo L., Malone D. Electroconvulsive therapy: what the internist needs to know. Cleveland Clinic Journal of Medicine 2007, 74:679-685.
33. Ristoff E., Larsson A. Inborn errors in the metabolism of glutathione. Orphanet Journal of Rare Diseases 2007, 2:16.
34. Ruhé H.G., Mason N.S., Schene A.H. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Molecular Psychiatry 2007, 12:331-359.
35. Sadock B., Sadock V., Ruiz P. Kaplan & Sadock's Comprehensive Textbook of Psychiatry 2009, Lippincott Williams & Wilkins, Philadelphia, PA. 9th edition.
36. Samuelsson M., Dahl M.L., Gupta R.C., Nordin C. Taurine in plasma and CSF: a study in healthy male volunteers. Amino Acids 2009, 36:529-533.
37. Samuelsson M., Vainikka L., Öllinger K. Glutathione in the blood and cerebrospinal fluid: A study in healthy male volunteers. Neuropeptides 2011, 45:287-292.
38. Savas H.A., Gergerlioglu H.S., Armutcu F., Herken H., Yilmaz H.R., Kocoglu E., Selek S., Tutkun H., Zoroglu S.S., Akyol O. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. The World Journal of Biological Psychiatry 2006, 7:51-55.
39. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. The American Journal of Psychiatry 1965, 122:509-522.
40. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. The Journal of Clinical Psychiatry 1998, 59:22-33.
41. Statistica. Version 8 2007. StatSoft, Tulsa, OK.
42. Wahlund B., von Rosen D. ECT of major depressed patients in relation to biological and clinical variables: a brief overview. Neuropsychopharmacology 2003, 28:21-26.
43. Wang J.F., Shao L., Sun X., Young L.T. Glutathione S-transferase is a novel target for mood stabilizing drugs in primary cultured neurons. Journal of Neurochemistry 2004, 88:1477-1484.
44. Wu H., Jin Y., Wei J., Jin H., Sha D., Wu J.Y. Mode of action of taurine as a neuroprotector. Brain Research 2005, 1038:123-131.
45. Yanik M., Erel O., Kati M. The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatrica 2004, 16:200-203.